Patents by Inventor Alan E. Walts

Alan E. Walts has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • EIF4E INHIBITORS AND USES THEREOF
    Publication number: 20230399322
    Abstract: The present invention provides compounds inhibiting eIF4E activity, and compositions and methods of using thereof.
    Type: Application
    Filed: June 15, 2023
    Publication date: December 14, 2023
    Inventors: Christopher L. VANDEUSEN, Alan E. Walts, Yat Sun Or
  • EIF4E inhibitors and uses thereof
    Patent number: 11753403
    Abstract: The present invention provides compounds inhibiting eIF4E activity, and compositions and methods of using thereof.
    Type: Grant
    Filed: March 3, 2021
    Date of Patent: September 12, 2023
    Assignee: PIC Therapeutics, Inc.
    Inventors: Christopher L. Vandeusen, Alan E. Walts, Yat Sun Or
  • EIF4E INHIBITORS AND USES THEREOF
    Publication number: 20220356178
    Abstract: The present invention provides compounds inhibiting eIF4E activity, and compositions and methods of using thereof.
    Type: Application
    Filed: March 3, 2021
    Publication date: November 10, 2022
    Inventors: Christopher L. VANDEUSEN, Alan E. WALTS, Yat Sun OR
  • Water insoluble derivatives of polyanionic polysaccharides
    Patent number: 5527893
    Abstract: A water insoluble, biocompatible composition composed of an acyl derivative of a polyanionic polysaccharide, a carbodiimide, and optionally, a nucleophile.
    Type: Grant
    Filed: December 23, 1992
    Date of Patent: June 18, 1996
    Assignee: Genzyme Corporation
    Inventors: James W. Burns, Robert Miller, Alan E. Walts
  • Phospholipid-saccharide conjugates
    Patent number: 5354853
    Abstract: Novel phospholipid-saccharide conjugates are produced by the reaction of a phospholipid derivative and an activated saccharide. The resulting conjugates can be used to make liposomes which are target-specific or resistant to degradation in vivo.
    Type: Grant
    Filed: March 12, 1993
    Date of Patent: October 11, 1994
    Assignee: Genzyme Corporation
    Inventors: Mark M. Staveski, Barbara Y. F. Wan, Alan E. Walts
  • Resolution of .alpha.-tertiary carboxylic acid esters using lipase from Candida lipolytica
    Patent number: 5202260
    Abstract: A method for the resolution of .alpha.-tertiary carboxylic acid esters by partial hydrolysis is disclosed. The partial hydrolysis is carried out by contacting the esters with an aqueous solution in the presence of a lipase derived from Candida lipolytica, and the hydrolysis product is separated from unreacted starting material to obtain the hydrolysis product or the unreacted starting material in enantiomerically enriched form.
    Type: Grant
    Filed: May 8, 1991
    Date of Patent: April 13, 1993
    Assignee: Genzyme Corporation
    Inventors: Christopher Yee, Todd A. Blythe, Alan E. Walts
  • Water insoluble derivatives of hyaluronic acid
    Patent number: 5017229
    Abstract: A water insoluble, biocompatible gel that includes the reaction product of hyaluronic acid, a polyanionic polysaccharide, and an activating agent.
    Type: Grant
    Filed: June 25, 1990
    Date of Patent: May 21, 1991
    Assignee: Genzyme Corporation
    Inventors: James W. Burns, Steven Cox, Alan E. Walts
  • Water insoluble derivatives of hyaluronic acid
    Patent number: 4937270
    Abstract: A method for making a water insouble bicompatible gel includes activating HA with an activating agent to form activated HA, and reacting the activated HA with a nucleophile, under conditions producing the water insoluble bicompatible gel. Also, a method for making a water insoluble biocompatible film includes providing a biocompatible gel made according to the above method, and drying the gel or compressing the gel under conditions permitting escape of water from the gel. Also, a water insoluble composition including HA is prepared without the use of any bifunctional or polyfunctional nucleophile.
    Type: Grant
    Filed: September 18, 1987
    Date of Patent: June 26, 1990
    Assignee: Genzyme Corporation
    Inventors: Raymond Hamilton, Ellen M. Fox, Raksha A. Acharya, Alan E. Walts
  • Resolution of glycidyl esters to high enantiomeric excess
    Patent number: 4923810
    Abstract: A method of resolving glycidyl esters to high enantiomeric excess involves fractionation of hydrolytic enzymes (e.g. lipases) to prepare biocatalysts with high enantioselectivity, and using these catalysts to selectively hydrolyze one enantiomer of the glycidyl esters. Also a method for fractionation includes stirring an aqueous solution of the enzyme with a solid inert adsorbent to provide an adsorbed and non-adsorbed enzyme fraction, where the non-adsorbed fraction displays a higher enantioselectivity than the crude non-fractionated enzyme. Also a composition composed of a glycidyl ester is obtained with an enantiomeric excess of greater than or equal to 97%.
    Type: Grant
    Filed: August 24, 1988
    Date of Patent: May 8, 1990
    Assignee: Genzyme Corporation
    Inventors: Alan E. Walts, Ellen M. Fox